0001493152-26-014036
SEC filingVycor Medical navigated a challenging fiscal year 2025, achieving revenue growth and a return to positive operating income, yet persistent net losses and negative free cash flow underscore significant ongoing financial pressures.
Revenue for fiscal year 2025 was $1.9 million, an increase of 17.2% compared to the prior year. This growth demonstrates the company's ability to expand its commercial activities. Gross profit followed this trend, rising 9.7% to $1.6 million. However, the gross margin for the year was 83.8%. Management attributes this margin level to several factors, including costs associated with validation and shipping, higher manufacturing costs for new production, and a shift toward a higher mix of international sales. A critical turnaround was achieved in operating performance, with operating income reaching $33.9 thousand, a substantial improvement from an operating loss in the prior year. This positive shift of 470.7% indicates progress in aligning the company's cost base with its revenue stream.
Despite the improvement in operating income, the company reported a net loss of $72.4 thousand for the year. This represents a 32.4% reduction in net loss compared to fiscal year 2024. Diluted earnings per share remained at -$0.01. Cash flow from operations was a use of cash totaling $13.5 thousand, a reversal from the prior year when operations provided cash. After accounting for capital expenditures of $5.2 thousand, free cash flow was negative $18.7 thousand. This dynamic highlights the ongoing challenge of converting accounting profits into sustainable operating cash generation, which is central to the company's liquidity position.
Management's discussion provides context for these financial results. The company has engaged Maxim Group LLC for advisory services, and the amortization of this agreement resulted in a specific charge during the year. Commentary also addresses cost pressures, noting that while rising raw material and labor costs may increase the cost of sales, inflation is not expected to materially affect the business. The financial statements have been prepared on a going concern basis, which assumes the company will continue its operations. The strategic focus includes the advisory relationship for potential strategic initiatives.
The company's financial position is characterized by the net loss and negative free cash flow reported for the year. Management's discussion frames the company's activities and plans within the context of its ongoing need to manage liquidity. The narrative accompanying the financial statements explicitly states they are prepared under the going concern assumption. This context is important for investors to understand the environment in which the company is executing its strategy to improve profitability and cash flow generation in the future.